Perioperative on-site haemoglobin determination: as accurate as laboratory values?

1996 ◽  
Vol 43 (8) ◽  
pp. 795-798 ◽  
Author(s):  
Melanie Jaeger ◽  
Ted Ashbury ◽  
Michael Adams ◽  
Peter Duncan
Keyword(s):  
Laboratory Values

scholarly journals Increasing the Density of Laboratory Measures for Machine Learning Applications

2020 ◽  
Vol 10 (1) ◽  
pp. 103
Author(s):  
Vida Abedi ◽  
Jiang Li ◽  
Manu K. Shivakumar ◽  
Venkatesh Avula ◽  
Durgesh P. Chaudhary ◽  
...  
Keyword(s):  
Hybrid Approach ◽  
Secondary Diagnosis ◽  
Healthcare Applications ◽  
Modeling Tools ◽  
Clostridioides Difficile ◽  
Laboratory Values ◽  
Diagnosis Codes ◽  
Problem Lists ◽  
Downstream Analysis ◽  
Laboratory Measures

Background. The imputation of missingness is a key step in Electronic Health Records (EHR) mining, as it can significantly affect the conclusions derived from the downstream analysis in translational medicine. The missingness of laboratory values in EHR is not at random, yet imputation techniques tend to disregard this key distinction. Consequently, the development of an adaptive imputation strategy designed specifically for EHR is an important step in improving the data imbalance and enhancing the predictive power of modeling tools for healthcare applications. Method. We analyzed the laboratory measures derived from Geisinger’s EHR on patients in three distinct cohorts—patients tested for Clostridioides difficile (Cdiff) infection, patients with a diagnosis of inflammatory bowel disease (IBD), and patients with a diagnosis of hip or knee osteoarthritis (OA). We extracted Logical Observation Identifiers Names and Codes (LOINC) from which we excluded those with 75% or more missingness. The comorbidities, primary or secondary diagnosis, as well as active problem lists, were also extracted. The adaptive imputation strategy was designed based on a hybrid approach. The comorbidity patterns of patients were transformed into latent patterns and then clustered. Imputation was performed on a cluster of patients for each cohort independently to show the generalizability of the method. The results were compared with imputation applied to the complete dataset without incorporating the information from comorbidity patterns. Results. We analyzed a total of 67,445 patients (11,230 IBD patients, 10,000 OA patients, and 46,215 patients tested for C. difficile infection). We extracted 495 LOINC and 11,230 diagnosis codes for the IBD cohort, 8160 diagnosis codes for the Cdiff cohort, and 2042 diagnosis codes for the OA cohort based on the primary/secondary diagnosis and active problem list in the EHR. Overall, the most improvement from this strategy was observed when the laboratory measures had a higher level of missingness. The best root mean square error (RMSE) difference for each dataset was recorded as −35.5 for the Cdiff, −8.3 for the IBD, and −11.3 for the OA dataset. Conclusions. An adaptive imputation strategy designed specifically for EHR that uses complementary information from the clinical profile of the patient can be used to improve the imputation of missing laboratory values, especially when laboratory codes with high levels of missingness are included in the analysis.

Normal Laboratory Values of CSF During Pregnancy

1979 ◽  
Vol 36 (7) ◽  
pp. 443-443 ◽  
Author(s):  
L. E. Davis
Keyword(s):  
Laboratory Values ◽  
Normal Laboratory

Analysis of biochemical laboratory values to determine etiology and prognosis in patients with subarachnoid hemorrhage: a clinical study

2018 ◽  
Vol 41 (2) ◽  
pp. 156-167 ◽  
Author(s):  
Mustafa Ogden ◽  
Bulent Bakar ◽  
Mustafa Ilker Karagedik ◽  
Ibrahim Umud Bulut ◽  
Cansel Cetin ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Clinical Study ◽  
Laboratory Values ◽  
Biochemical Laboratory

Changes in Laboratory Values in Patients Receiving Total Parenteral Nutrition

1990 ◽  
Vol 21 (2) ◽  
pp. 97-102
Author(s):  
Deborah A. Perry ◽  
Rodney S. Markin ◽  
Scott G. Rose ◽  
Jerald R. Schenken
Keyword(s):  
Parenteral Nutrition ◽  
Total Parenteral Nutrition ◽  
Laboratory Values

Preoperative evaluation of coagulation status in neuromodulation patients

2021 ◽  
pp. 1-7
Author(s):  
Amir Hadanny ◽  
Zachary T. Olmsted ◽  
Anthony M. Marchese ◽  
Kyle Kroll ◽  
Christopher Figueroa ◽  
...  
Keyword(s):  
Laboratory Tests ◽  
Preoperative Evaluation ◽  
Preoperative Assessment ◽  
New Anticoagulants ◽  
Laboratory Values ◽  
Normal Ranges ◽  
Hematological Analysis ◽  
Coagulation Status ◽  
Pump Implantation ◽  
Deep Brain

OBJECTIVE The incidence of hemorrhage in patients who undergo deep brain stimulation (DBS) and spinal cord stimulation (SCS) is between 0.5% and 2.5%. Coagulation status is one of the factors that can predispose patients to the development of these complications. As a routine part of preoperative assessment, the authors obtain prothrombin time (PT), partial thromboplastin time (PTT), and platelet count. However, insurers often cover only PT/PTT laboratory tests if the patient is receiving warfarin/heparin. The authors aimed to examine their experience with abnormal coagulation parameters in patients who underwent neuromodulation. METHODS Patients who underwent neuromodulation (SCS, DBS, or intrathecal pump implantation) over a 9-year period and had preoperative laboratory values available were included. The authors determined abnormal values on the basis of a clinical protocol utilized at their practice, which combined the normal ranges of the laboratory tests and clinical relevance. This protocol had cutoff values of 12 seconds and 39 seconds for PT and PTT, respectively, and < 120,000 platelets/μl. The authors identified risk factors for these abnormalities and described interventions. RESULTS Of the 1767 patients who met the inclusion criteria, 136 had abnormal preoperative laboratory values. Five of these 136 patients had values that were misclassified as abnormal because they were within the normal ranges at the outside facility where they were tested. Fifty-one patients had laboratory values outside the ranges of our protocol, but the surgeons reviewed and approved these patients without further intervention. Of the remaining 80 patients, 8 had known coagulopathies and 24 were receiving warfarin/heparin. The remaining 48 patients were receiving other anticoagulant/antiplatelet medications. These included apixaban/rivaroxaban/dabigatran anticoagulants (n = 22; mean ± SD PT 13.7 ± 2.5 seconds) and aspirin/clopidogrel/other antiplatelet medications (n = 26; mean ± SD PT 14.4 ± 5.8 seconds). Eight new coagulopathies were identified and further investigated with hematological analysis. CONCLUSIONS New anticoagulants and antiplatelet medications are not monitored with PT/PTT, but they affect coagulation status and laboratory values. Although platelet function tests aid in a subset of medications, it is more difficult to assess the coagulation status of patients receiving novel anticoagulants. PT/PTT may provide value preoperatively.

scholarly journals 2: Laboratory Values From Positive EBOV Patients

2015 ◽  
Vol 143 (suppl_1) ◽  
pp. A001-A001
Author(s):  
Emily L. Ryan ◽  
Charles E. Hill
Keyword(s):  
Laboratory Values
Sign in / Sign up

Export Citation Format

Share Document